KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $2.7 million.

  • Halozyme Therapeutics' Depreciation & Amortization (CF) rose 384.62% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 234.28%. This contributed to the annual value of $10.3 million for FY2024, which is 720.72% down from last year.
  • Halozyme Therapeutics' Depreciation & Amortization (CF) amounted to $2.7 million in Q3 2025, which was up 384.62% from $2.7 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $2.9 million for Q4 2023, and its period low was $700000.0 during Q3 2021.
  • In the last 5 years, Halozyme Therapeutics' Depreciation & Amortization (CF) had a median value of $2.6 million in 2024 and averaged $2.0 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 1800.0% in 2021, then skyrocketed by 23105.67% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Depreciation & Amortization (CF) stood at $776000.0 in 2021, then soared by 231.06% to $2.6 million in 2022, then increased by 12.88% to $2.9 million in 2023, then decreased by 7.24% to $2.7 million in 2024, then rose by 0.37% to $2.7 million in 2025.
  • Its Depreciation & Amortization (CF) was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.7 million in Q1 2025.